Drug Trial Radar · NCT03340506
Dabrafenib and/or Trametinib Rollover Study
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jan 26, 2018
Primary completion
Dec 28, 2032
Study completion Dec 28, 2032
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 13, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.
Conditions
- Melanoma
- Non Small Cell Lung Cancer
- Solid Tumor
- Rare Cancers
- High Grade Glioma
Interventions
dabrafenibDrug
dabrafenib is available in capsules (50mg and 75mg) taken twice a day
trametinibDrug
trametinib is available in tablets (0.5mg, 2mg dose)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurences of adverse events to evaluate long term safety and tolerability of dabrafenib, trametinib or combinationTime frame: Baseline up to approximately 10 years after the first subject's first visit, or will remain open until treatment becomes commercially available and reimbursed, or another access program becomes available, whichever comes first.
Locations
37 sites in 15 countries. Site status is shown where the registry gives one.
Honor Health Research Institute
Scottsdale, Arizona · Active not recruiting
National Institute Of Health
Bethesda, Maryland · Active not recruiting
James Cancer Hospital and Solove Research Institute Ohio State
Columbus, Ohio · Completed
Mary Crowley Cancer Research
Dallas, Texas · Completed
Novartis Investigative Site
Caba, Buenos Aires, Argentina · Completed
Novartis Investigative Site
Innsbruck, Tyrol, Austria · Active not recruiting
Novartis Investigative Site
Toronto, Ontario, Canada · Recruiting
Novartis Investigative Site
Beijing, China · Completed
Novartis Investigative Site
Brno, Czechia · Active not recruiting
Novartis Investigative Site
Prague, Czechia · Active not recruiting
Novartis Investigative Site
Copenhagen, Denmark · Active not recruiting
Novartis Investigative Site
Lyon, France · Active not recruiting
Novartis Investigative Site
Nantes, France · Completed
Novartis Investigative Site
Paris, France · Active not recruiting
Novartis Investigative Site
Paris, France · Completed
Novartis Investigative Site
Villejuif, France · Recruiting
Novartis Investigative Site
Augsburg, Germany · Active not recruiting
Novartis Investigative Site
Berlin, Germany · Completed
Novartis Investigative Site
Essen, Germany · Active not recruiting
Novartis Investigative Site
Hamburg, Germany · Completed
Novartis Investigative Site
Hamburg, Germany · Active not recruiting
Novartis Investigative Site
Heidelberg, Germany · Active not recruiting
Novartis Investigative Site
Mannheim, Baden-Wurttemberg, Germany · Completed
Novartis Investigative Site
Budapest, Hungary · Completed
Novartis Investigative Site
Debrecen, Hajdu Bihar Megye, Hungary · Completed
Novartis Investigative Site
Kashiwa, Chiba, Japan · Completed
Novartis Investigative Site
Chuo Ku, Tokyo, Japan · Completed
Novartis Investigative Site
Utrecht, Netherlands · Active not recruiting
Novartis Investigative Site
Rotterdam, South Holland, Netherlands · Completed
Novartis Investigative Site
Moscow, Russia · Active not recruiting
Novartis Investigative Site
Barcelona, Spain · Recruiting
Novartis Investigative Site
Madrid, Spain · Active not recruiting
Novartis Investigative Site
Madrid, Spain · Recruiting
Novartis Investigative Site
Madrid, Spain · Completed
Novartis Investigative Site
Madrid, Spain · Recruiting
Novartis Investigative Site
Valencia, Spain · Active not recruiting
Novartis Investigative Site
Songkhla, Hat Yai, Thailand · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.